founded in 2020.
We are assembling a team of experienced scientists, clinicians, and industry leaders with experience in cardiovascular medicine, patient care, and diagnostics.
Peter M. DiBattiste, MD, FACC, FAHA
Pete co-founded Prolocor and has served as the company’s CEO since 2020. Prior to founding Prolocor, he spent 14 years in a cardiovascular leadership role with Janssen R&D, mostly recently as Global Development Head of Cardiovascular and Head of Thrombosis Disease Area Stronghold. At Janssen, Pete oversaw numerous early and late-stage cardiovascular development programs, heading a group of 35 physicians and scientists specializing in cardiovascular drug development.
Earlier in his career, Pete was a member of cardiovascular research and development groups at AstraZeneca and Merck. Prior to joining the industry, Pete practiced medicine and was an Adjunct Professor at the University of Pennsylvania School of Medicine, The Lankenau Hospital, and Hahnemann University Hospital. He has authored more than 40 peer-reviewed publications in cardiovascular medicine.
Pete completed his Fellowship in Cardiology at the University of Pennsylvania. He holds an MD from Harvard Medical School.
David J. Schneider, MD, FACC, FAHA
David co-founded Prolocor and has served as the company’s CSO since 2020. David is a Professor of Medicine at the University of Vermont and has been at the University for the past 25+ years. Since 2013, David has also served as Director of the Cardiovascular Research Institute at the University of Vermont and Medical Director of Cardiovascular Services at the University of Vermont Health Network.
For many years, David has had an active research program focused on causal connections between diabetes and heart disease, and the role of platelets in the development and progression of atherosclerosis. He holds several patents including the use of a novel biomarker, FcɣRIIa, as a precision tool to guide care of patients with atherosclerotic vascular disease.
He has published more than 160 manuscripts and authored numerous chapters. David completed his Fellowship in Cardiology at Washington University in St. Louis. He holds an MD from the University of Cincinnati.
Edward L. Rosen
Ed has a 25-year background in life sciences as a leader of transformational growth, organizational build-out through commercialization, innovation and product development across Pharmaceutical, Device and Diagnostic businesses in key markets, channels and geographies.
Most recently, Ed served as Chief Strategy & Commercial Officer at Clinical Genomics. Prior to that, he served as Executive-in-Residence at Columbia University (Office of Technology Ventures) and President & CEO of Elucida Oncology, where he built the company through securing financing to advance its programs. Ed also spent nearly 20 years with Johnson & Johnson and Smith & Nephew in various positions, departing as Worldwide Vice President of Marketing at Mentor Worldwide, a Johnson & Johnson company.
Ed holds a BA (Hons) in Business Studies from the University of Lincoln in the UK.
Barbara A. Carlin, CPA, MBA
Barb has a 25-year background in life sciences, leading finance and accounting management from start-ups to commercial-stage companies. In addition to leading Danforth’s Mid-Atlantic practice, Barb serves as a Consultant CFO for several of her clients.
Prior to joining Danforth, Barb served as CFO of Enterin, Chief Accounting Officer at Egalet Corporation (Zyla Life Sciences) where she helped build the infrastructure for an IPO and commercial launches. She also held finance leadership roles at SOBI, Topaz (acquired by Sanofi-Pasteur), Genaera and Vicuron (acquired by Pfizer). She began her career as an auditor at Deloitte.
Barb is a CPA and holds a BS in Accounting and MBA in Pharmaceutical & Healthcare Marketing from St. Joseph’s University in Philadelphia. Barb is on the Board of Directors of Life Sciences Pennsylvania and on the Board of Advisors for Life Science Cares Philadelphia.
David Esposito, MBA
David is President and Chief Executive Officer of ONL Therapeutics.
He is an experienced healthcare executive who has built and scaled multiple companies that have resulted in successful exits. David is the former CEO of Armune BioScience, where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. Armune BioScience was sold to Exact Sciences in 2017. He was also President of Phadia US Inc. and he played a pivotal role in the sale of the business to Thermo Fisher Scientific in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing, and commercial strategy for the US Division.
David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his BS degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.